Triopsy Medical

Triopsy™ Medical, Inc.™ emerged under the guidance of renowned experts in the field of urology. The driving force behind Triopsy™ was the desire to bridge the gap between overtreating and undertreating prostate cancer, delivering a precision tool to enable physicians to diagnose patients more accurately, aligning treatment with their precise disease state. Triopsy™ introduced a groundbreaking system comprising a fully adjustable 5.5cm biopsy needle, an adaptable and reusable biopsy actuator, and an Integrated Pathology System (IPS). The Triopsy™ System empowers urologists to obtain longer, unfragmented tissue samples, significantly elevating the accuracy of locating and identifying prostate cancer lesions. The innovations contained within Triopsy’s Needle design have been recognized with issued patents. Furthermore, the Triopsy™ Biopsy Actuator offers physicians the capability to adjust the length of the biopsy core from 1.7 to 5.5cm, thus enhancing control and precision throughout the entire procedure. Triopsy™ envisions a paradigm shift in the standard of care for prostate biopsies. Triopsy™ Medical™ was established to confront the pressing need for a more precise prostate cancer diagnosis.